natgillin/translations-raw huggingface dataset:
depending on the result of the comparison, modification or no modification of at least one of the residual data items of the subset. 
- < uovisnosti o rezultatu navedene usporedbe, modificiranje (C10) ili ne modificiranje barem jedne od preostalih stavki podataka iz navedenog podskupa,
attaching an isosubstrate of an isoprenoid transferase to an active agent; and enzymatically reacting, using the isoprenoid transferase, the expressed protein with the active agent attached to the isosubstrate. 
(D vezanje izosupstrata izoprenoid transferaze na aktivno sredstvo; i (g) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu se eksprimirano antitijelo s aktivnim sredstvom veže na izosupstrat.
The combination of claim 1, wherein the through bore communicates with the interior of the modified casing coupling by a port provided in a sidewall of the modified casing coupling. 
Kombinacija iz zahtjeva 1, pri čemu je prolazna bušotina (142) u vezi s unutrašnjošću modificirane spojke za zaštitne cijevi (136) putem otvora predviđenog u bočnoj stjenki (140) modificirane spojke za zaštitne cijevi.
In certain alternative embodiments, the agent is an antibody that specifically binds to the extracellular domain of two or more human LGR proteins. 
Izolirano monoklonalno protutijelo, naznačeno time, da se specifično veže na izvanstaničnu domenu od receptora
Apparatus for decoding an image by using large transformation units 
UREĐAJ ZA DEKODIRANJE SLIKE KORIŠTENJEM VELIKIH TRANSFORMACIJSKIH JEDINICA
The FTI for use of any one of claims 1 to 4, wherein said method comprises determining the presence of a H-Ras mutation in a sample from said human. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu metoda sadrži utvrđivanje pristunosti H-Ras mutacije u uzorku uzetom od navedenog subjekta.
US4481218 discloses a preparation of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate, which comprises passage through a column with a strongly basic ion exchange resin. 
Uporaba spoja formule (I), naznačena time, da jest za sintezu 3-(2,2,2-trimetilhidrazin)propionat dihidrata.
or, if m and s are 2, m is 3 and s is 1, or m is 4 and s is 0, R6 is CH2—CH—(CH2)2 which is bound with one CH2 to the cycloalkyl ring and the two other CH2 are bound to different carbon atoms of the cycloalkyl ring; and, if m is 3 and s is 3, R6 are two methylene groups bound to different carbon atoms of the cycloalkyl ring, wherein the methylene groups or the CH2—CH—(CH2)2 group are bound to carbon atoms of the cycloaalkyl ring such that they form an adamantane system of the formula wherein L can be bound to any secondary or tertiary carbon atom and wherein the bicyclic ring system or adamantane system is unsubstituted or optionally substituted by R9; 
Ry je CH;-CH-(CH>),, koji je vezan s jednim CH, na cikloalkilni prsten i the druga dva CH, su vezana na različite atome ugljika u cikloalkilnom prstenu; iakojem3,asje3, Rg su dvije metilenske skupine, vezane na različite atome ugljika u cikloalkilnom prstenu, gdje su metilenske skupine ili skupina CH,-CH-(CH.), tako vezani na atome ugljika u cikloalkilnom prstenu da tvore adamantanski sustav formule gdje L može biti vezan na bilo koji sekundarni ili tercijarni atom ugljika i gdje biciklički sustav prstena ili adamantanski sustav nije supstituiran ili je izborno supstituiran s Ro, Rio jo
The method of claim 63, wherein R5 is selected from the group consisting of: 
Spoj prema zahtjevu 1, naznačen time da ima strukturu odabranu iz skupine koja sadrži:
Number of 42, XY cells 
(21) Broj predmeta:
A sodium salt of the compound of the following formula (1): 
Natrijeva sol, naznačena time, da je od spoja sljedeće formule (1):
The container according to any of the preceding claims, wherein the pharmaceutical composition is a liquid HSA-free formulation comprising 30 to 100 µg/ml of interferon-B, an isotonicity agent, 0.1 to 2 mg/ml of a surfactant, at least 0.12 mg/ml of an antioxidant and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0. 
Spremnik prema bilo kojem od prethodnih zahtjeva, naznačen time da farmaceutski pripravak je tekuća formulacija bez-HSA koja sadrži 30 do 100 ug/ml interferona-f, izotonično sredstvo, 0.1 do 2 mg/ml surfaktanta, barem 0.12 mg/ml antioksidanta i pufersku otopinu koja je sposobna održavati pH tekuće formulacije na vrijednosti između 3.0 1 4.0.
R4a-Y (X) where R4a represents an R4 group as defined in claim 1 optionally in protected form, and Y is a leaving group such as Cl, Br, I, OSO2CH3, OSO2CF3 or O-Tosyl. 
Ru=Y (X) gdje Ra, predstavlja skupinu R, kako je definirana u patentnom zahtjevu 1 koja može biti u zaštićenom obliku, te Y jest izlazna skupina kao što je Cl, Br, I, OSO;CH.3, OSO2CF; ili O-tosil.
The pallet as claimed in claim 3, wherein those zones in which the profile is bent at 90°, pieces of profile (2) which form said first, second and third component (4, 6, 8, 60, 62, 64) comprise first apertures (38) provided to facilitate bending. 
Paleta u skladu s jednim ili više patentnih zahtjeva 2-7, naznačena time što u zonama u kojima je profil svinut pod 90" komadi profila (2) koji čine navedenu prvu, drugu 1 treću komponentu (4, 6, 8, 60, 62, 64) imaju prve otvore (38), načinjene da se olakša savijanje.
by an oral route, for example, in the form of tablets, capsules, beads, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations, or they can be administered intranasally or in transdermal patches. 
oralnim putem, na primjer, u obliku tableta, kapsula, globula, granula ili praška, ili se može primjenjivati parenteralnim putem u obliku injektabilnih preparata, ili se može primjenjivati intranazalno ili u transdermalnim flasterima.
The method of claim 11, wherein the mouse MHC a and B polypeptides are respectively encoded by mouse H-2E a and B genes, and a human portion of the chimeric MHC II complex is encoded by human HLA-DR4 a and B genes. 
Metoda 1z zahtjeva 11. gdje mišje MHC a odnosno (8 polipeptide kodiraju mišji geni H-2E a 1 f, a ljudski dio kimernog MHC II kompleksa kodiraju ljudski geni HLA-DR4 4.1 f.
with a compound of formula VIII 
(VII) reagira sa spojem formule VIII
in a compatible solvent to stereoselectively produce a compound of formula (I). 
u kompatibilnom otapalu, da se stereoselektivno proizvede spoj formule (1).
In the FIGURE is schematically shown a process for producing sucrose and ethanol from sugar beet according to the invention. DETAILED DESCRIPTION OF THE INVENTION In the crystallisation process according to the invention, a solution of a water-soluble compound in a mixture of water and a solvent in which the water-soluble compound has a lower solubility than in water, is provided in a crystallisation vessel. 
Postupak kristalizacije spoja topivog u vodi iz otopine koji sadrži sljedeće korake: a) pružanje, u posudi za kristalizaciju, otopine spoja topivog u vodi u mješavini vode i otopine u kojoj spoj topiv u vodi ima slabiju topljivost nego u vodi; b) provođenje faze isparavanja mješavine kroz sorpcijsku zonu koja sadrži sorpcijsko sredstvo za vodenu paru kako bi selektivno adsorbiralo vodu iz faze isparavanja kako bi se u fazi isparavanja izdvojila voda i povećao udio otopine i vodom zasićenog vodenog sorpcijskog sredstva;
The compound or the pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein Het represents a group of formula A represents a methylene group; 
Spoj, ili njegova farmaceutski prihvatljiva sol, u skladu s patentnim zahtjevom 1, naznačen time što Het predstavlja skupinu formule [image], A predstavlja metilensku skupinu;
contacting the antigen presenting cells of step (iii) with a T-cell to evaluate the ability of the peptide to stimulate the T-cells; and 
stavljanja u kontakt sa stanicama koje prezentiraju antigen iz koraka (iii) s T-stanice kako bi se procijenila sposobnost peptida da stimulira T-stanice; i
According to the invention, the groove structures are filled before mechanical machining with a filling medium which is not removed again from the groove structures until after mechanical machining. 
Prema izumu, prije mehaničke strojne obrade brazdaste strukture se pune s punilom koje se ponovno odstruje iz brazdastih struktura tek nakon mehaničke strojne obrade.
The layers were separated and the IPAc layer was washed sequentially with H2O (500mL), saturated NaHCO3 (200mL) and H2O (4x500mL) and then filtered through a silica gel pad. 
Slojevi taloga su bili odvojeni 1 sloj taloga IPAc je bio ispran nakon toga s H2O (500 mL), zasićenim NaHCO; (200 mL) i H2O (4x500 mL) i tada filtriran kroz filtar silikagela.
The ABM or antibody of item 24, wherein at least about 20% to about 50% of the N-linked oligosaccharides in the Fc region are bisected, nonfucosylated. 
Protutijelo u skladu sa zahtjevom 7, naznačeno time, da su najmanje 20% do 50% N-vezanih oligosaharida u Fc regiji prepolovljeni, nefukozilirani.
a therapeutically effective amount of the anamorelin monohydrochloride of claims 1,2,or 3; and 
terapeutski efikasnu količinu anamorelin monohidroklorida prema patentnim zahtjevima 1, 2 ili 3; i
Such non-pharmaceutically acceptable salt forms also form part of the invention. 
Takve farmaceutski neprihvatljive soli također čine dio izuma.
adding the product of step (ii) to a portion of the mixture obtained in step (i); 
(1ii) dodavanje produkta iz koraka (1i) dijelu smjese dobivene u koraku (i);
A method for treatment of an inflammatory disease which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions. 
Uporaba spoja prema jednom od bilo kojih zahtjeva od 1 do 11, naznačena time da je za proizvodnju lijeka namijenjenog liječenju upalnih bolesti poput reumatskog artritisa, konjunktivitisa, reumatskog spondilitisa, artroze, gihta i drugih artritičnih stanja.
Process according to any of the previous claims, wherein a second membrane is used to separate sulphuric acid from a stream rich in monosaccharides, which is obtained after hydrolysis of said organic matter using sulphuric acid, thus producing a weak sulphuric acid stream, after which said stream rich in monosaccharides is fed to a fermentor and said weak sulphuric acid stream is fed to an anaerobic acidification and sulphate reduction step. Use of an anion selective membrane in the separation of sulphuric acid from a mixture of carbohydrates and sulphuric acid. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time, da se koristi druga membrana za odvajanje sumporne kiseline od toka bogatog monosaharidima, koji se dobije nakon hidrolize spomenutih organskih tvari uporabom sumporne kiseline, te time proizvodnjom toka slabe sumporne kiseline, nakon čega se spomenuti tok bogat monosaharidima ubacuje u fermentor, a spomenuti tok slabe sumporne kiseline se ubacuje u fazu anaerobne acidifikacije i sulfatne redukcije.
An example of such a not mammal-derived compound is cod-liver oil. Therefore in one embodiment of the current invention the medium used in the cultivation is a serum-free medium, or a serum-free medium supplemented with defined mammal-derived components, or an mammal-derived component free medium, or a protein-free medium, a protein-free medium supplemented with defined mammal-derived components, or a chemically defined medium, or a mammal-derived component free medium, or a defined protein-free medium. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 17 i 19 do 27, naznačen time, da je medij korišten u kultivaciji medij bez seruma, ili medij bez seruma dopunjen definiranim komponentama dobivenih iz sisavaca, ili medij bez komponenti životinjskog porijekla, ili medij bez proteina, ili medij bez proteina dopunjen definiranim komponentama životinjskog porijekla, ili kemijski definirani medij, ili medij bez komponenti dobivenih od sisavaca, ili definirani medij bez proteina.
a coating disposed on the second blend, the coating comprising a coating of a second oil on the one or more herbs, spices or flavor enhancers, the second oil having a melting point below 20° C. 
66 do 99%, težinski, biljne ili životinjske masti s talištem iznad 20 *C; 1 ili. jednog ili više začinskog bilja, začina i pojačivača okusa, gdje se začinsko bilje, začine i pojačivače okusa prekrije uljem.
Optionally, the maturing step comprises storing the dehydrated collagen at a temperature of at least 40°C for a period of at least six weeks. 
Zreli kolagen prema patentnom zahtjevu 1, naznačen time što se je dehidrirani kolagen pohranjen na temperaturi od najmanje 40 *C kroz razdoblje od najmanje šest tjedana i uz relativnu vlažnost manju od 80%.
a cytotoxic agent, optionally a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme; or 
citotoksičko sredstvo, opcijski kemoterapeutsko sredstvo, funkcionalni dio lijeka, antibiotik, radioaktivni izotop, i nukleolitički enzim; ili
An in vitro diagnostic method comprising a fully human anti-VAP-1 antibody according to claim 1 or 2. Use of a fully human anti-VAP-1 antibody according to claim 1 for the manufacture of a pharmaceutical composition for treating a VAP-1 mediated inflammatory disorder selected from the group consisting of arthritides and connective tissue diseases, inflammatory bowel diseases, dermatoses, multiple sclerosis, inflammatory neuropathy, inflammatory myopathy, acute disseminated encephalomyelitis, vasculitis of the central nervous system, Sjögrens syndrome, diabetes, systemic lupus erythematosus, asthma, inflammatory liver disease, Graves disease and thyroiditis. 
In vitro dijagnostička metoda koja sadrži potpuno ljudsko anti-VAP-1 antitijelo prema bilo kojem od zahtjeva 1 do Uporaba potpuno ljudskog anti-VAP-1 antitijela prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje upalnog poremećaja posredovanog VAP-1 izabranog iz skupine koja se sastoji od artritisa i bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjogrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
The method according to claim 17, further comprising injecting liquid into the mixture such that the mixture comprises sand and water having a density of more than 1650 kg/m3. 
Postupak sukladno zahtjevu 16 pri čemu mješavina sadrži pijesak 1 vodu gustoće više od 1650 kg/m3.
and converting a compound of formula [52] to a compound of formula [1-3-2] 
(i) prevođenju spoja formule [52] u spoj formule [1-3-2] ns
a compound selected from the group consisting of sulfonylureas, including their respective isomers a s well as their respective environmentally compatible salts or esters or amides or other derivatives; 
Sinergistička herbicidna smjesa koja sadrži imazamoks, njegove odgovarajuće izomere, kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom;
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1. 
Hi Farmaceutski sastav koji sadrži farmaceutski prihvatljiv nosač i spoj iz zahtjeva 1.
A compound of formula (I) for use as claimed in claim 9 for use in treating asthma or chronic obstructive pulmonary disease. 
Spoj formule (I) za upotrebu sukladno patentnom zahtjevu 9 za liječenju astme ili kronične opstruktivne bolesti pluća.
The composition according to claim 8, wherein the CB1 cannabinoid receptor agonist is selected from the group consisting of HU-210 and arachidonyl-2'-chloroethylamide (ACEA). 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što se agonist kanabinoidnog receptora CB, bira iz skupine koju čine HU-210 i arahidonil-2'-kloretilamid (ACEA).
A compound of the formula: or a pharmaceutically acceptable salt thereof, for use in combination with a NS5B polymerase inhibitor and a NS3 protease inhibitor in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder. 
Spoj formule: HR P20161242 T1 ča Bb T ili njegova farmaceutski LL sol, za primjenu u kombinaciji sa NS5B polimeraznim inhibitorom i NS3 proteaznim inhibitorom u profilaktičkom ili terapijsko liječenju hepatitisa C ili poremećaja povezanog sa hepatitisom (A 16.
A peptide according to any one of claims 1 to 5, a nucleic acid or expression vector according to claim 6, a host cell according to claim 7, a CTL according to claim 11 or 12, or an antibody according to claim 13 for use as a medicament in the treatment of cancer, such as, for example, gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 12 za upotrebu u liječenju karcinoma, kao što su gastrični, gastrointestinalni, kolorektalni karcinomi te karcinomi gušterače, pluća ili bubrega.
The expansion joint according to claim 1, wherein the first vertically oriented corrugated plate of the upper portion and the second vertically oriented corrugated plate of the upper portion and the first vertically oriented corrugated plate of the lower portion and the second vertically oriented corrugated plate of the lower portion are formed of a substantially rigid material. The expansion joint according to claim 8, wherein the substantially rigid material is a metallic material. The expansion joint according to claim 8, wherein the substantially rigid material is steel. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time da su razdjelni elementi (4, 6) gornjeg dijela i valovite ploče (15, 17) donjeg dijela oblikovani od u biti čvrstog materijala; posebno od metalnog materijala; posebno od čelika. Kompenzacijski spoj prema bilo kojem od zahtjeva 1 do 16, naznačen time da su razdjelni elementi gornjeg dijela, kao što su gornje valovite ploče (4, 6), oblikovani od otpornijeg materijala na trošenje u usporedbi s valovitim pločama (15, 17) donjeg dijela.
One embodiment of the invention is an assay for determining for a female subject the implantation potential of embryos obtained or to be obtained by assisted fertilisation comprising: measuring, for a plurality of ooctyes collected from said subject, the level of follicular fluid granulocyte-colony stimulating factor (G-CSF) present in the follicular fluid (FF) of a follicle of each collected oocyte; and 
Pokus kojim se kod ispitanica ženskog spola određuje implantacijski potencijal embrija koji su dobiveni ili se trebaju dobiti medicinski potpomognutom oplodnjom, naznačen time, da uključuje: (i) mjerenje, kod većeg broja oocita dobivenih od navedene ispitanice, razine granulocitnog faktora rasta u foliklarnoj tekućini (follicular fluid granulocyte-colony stimmulating factor, G-CSF) nazočne u folikularnoj tekućini (FF) folikula svakog od prikupljenih oocita; te
the dairy base provided in step a) comprises a total amount of protein of at least 7% (w/w), the solids of a denatured whey protein composition according to any of the claims 1-5in an amount of at least 2% (w/w), and a total amount of CMP of at least 2% (w/w) relative to the total amount of protein, or 
ID) mliječna baza osigurana u koraku a) sadrži ukupnu količinu proteina od najmanje 7 % (tež./tež.), čvrste tvari pripravka denaturiranog proteina sirutke u skladu s bilo kojim od patentnih zahtjeva 1-5 u količini od najmanje 2 % (tež./tež.), te ukupnu količinu CMP od najmanje 2 % (tež./tež.) u odnosu na ukupnu količinu proteina, ili
A method for improving the hydrophobic properties of a fiber cement product comprising at least one profiled surface, said method comprises the steps of 
osiguravanje vlaknastog cementnog proizvoda koji sadrži najmanje jednu profiliranu površinu, navedena profilirana površina sadrži udubljene dijelove ili površine, ograničene bočnim stranama koje imaju kut između udubljene površine i bočne strane veće od 90% i manje od 160";
The beehive lid according to claim 1, wherein a clear or riddled cover is adapted to slide in, after lifting the removable cover off, in order to watch the inside of the hive without allowing the bees to exit. 
Poklopac košnice prema zahtjevu 1, koji ima unutarnji pokrov (48), koji se može odstraniti, naznačen time, da se ispod pomičnog pokrova može umetnuti proziran ili perforiran pokrov i da se nakon njegovog podizanja može promatrati unutrašnjost košnice, a da pritom pčele ne izlaze.
The process of claim 1 wherein R′ is tri (C1-C3 alkyl)silyl and R is C1-C4 alkoxycarbonyl or benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from the group consisting of halogen, cyano, trifluoromethyl. The process of claim 4 wherein R′ is trimethylsilyl and R is tert-butoxycarbonyl. 
Postupak iz patentnog zahtjeva 7, naznačen time da u spoju formule (VI) R' jest tri(C;-C; alkil)silil, a R jest C;-C alkoksikarbonil ili benziloksikarbonil koji je na aromatskom prstenu supstituiran s do tri supstituenta odbranih od sljedećih: halogen, cijano 1 trifluometilna skupina.
—(C═O)m—On-heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R13, 
-<(C=0),-O,-heterociklus, gdje je heterociklus nesupstituiran ili supstituiran sa jednim ili više supstituenata izabranih od R",
wherein the pinanediol boronic ester is obtained by trans-esterification of a pinacol boronate of formula (XXXIII): and optionally 
te opcionalno, pritom se pinandiol ester boronske kiseline dobiva putem trans-esterifikacije pinakol boronata formule (XXXIII):
A polypeptide comprising a hybrid C-terminal OspA (outer surface protein A of Borrelia) fragment, wherein the hybrid C-terminal OspA fragment consists, from the N- to C-terminal direction, of a first OspA portion consisting of amino acids 125-176 or amino acids 126-175 of OspA from a Borrelia strain that is not the corresponding fragment of B. garinii, strain PBr, with SEQ ID NO: 8, and 
Polipeptid koji sadrži fragment hibridnog C-terminalnog OspA (vanjskog površinskog proteina A Borrelia), gdje se hibrid C-terminalni OspA fragment sastoji od N-C-terminalnog smjera, od i) prvi OspA dio koji se sastoji od aminokiselina 125-176 ili amino kiselina 126-175 OspA iz Borrelia soja koji nije odgovarajući fragment B. garinii soja, PBr sa SEQ ID NO: 8,1 ii) - drugi dio OspA koji se sastoji od -
A composition of claim 16, comprising an additional therapeutic agent. 
Farmaceutski sastav prema zahtjevu 17, koji sadrži dodatni terapeutski agens.
The garment material according to any one of claims 11 to 13 wherein the dressing compound comprises an encapsulated mixture of Cajiput, Cypress Palmarosa, Rose, Geranium, Pine and/or Lavender oils and/or an encapsulated blend of Juniper, Sage, Witch Hazel, Cistus, Tea Tree, Eucalyptus and/or Basil oils. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, 11 ili 12, ili odjevni materijal u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačeni time što smjesa eteričnih ulja sadrži antiperspirantno eterično ulje, kojeg se bira iz skupine koju čine ulja borovice, kadulje, vještičje lijeske, cistusa, čajevca, eukaliptusa i/ili bosiljka.
Ascorbic acid is used as an antioxidant in pharmaceutical manufacturing and in the food industry. 
Askorbinska kiselina se rabi kao antioksidans u farmaceutskoj proizvodnji te u prehrambenoj industriji.
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; wherein the method comprises treating a compound of formula (15): 
-CF3 om ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese; naznačen time što se postupak sastoji u: a) obradi spoja formule (7): jej nr
Conventional ("typical") antipsychotics block D2 receptors nonselectively in all four areas of the brain. 
Uobičajeni (,tipični") antipsihotici blokiraju D2 receptore neselektivno u sva četiri područja mozga.